Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

Cool and also collected

Thymosin α1 may be a rare one-stop shop for cystic fibrosis

April 13, 2017 10:11 PM UTC

A Nature Medicine study published this week shows the immune-modulating peptide thymosin α1 provides unexpected improvements in the dysfunctional ion channel that causes cystic fibrosis, and could lead to a single agent therapy to compete with the combinations gaining ground in the clinic.

The University of Perugia and University San Raffaele researchers who led the study have patented the findings, and plan to test the compound in early stage CF patients by the end of the year. The team is also in discussion with SciClone Pharmaceuticals Inc., which markets Zadaxin thymalfasin, a synthetic version of thymosin α1, for hepatitis B (HBV), hepatitis C (HCV) and as an adjuvant for cancer therapies...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article